^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KIT V559A

    i
    Other names: KIT, KIT proto-oncogene receptor tyrosine kinase, C-Kit, CD117, PBT, SCFR, Stem Cell Factor Receptor, V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
    Entrez ID:
    3815
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Associations

    News

    Trials
    27d
    Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557
    |
    paclitaxel • Tasigna (nilotinib)
    11ms
    Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (clinicaltrials.gov)
    P2, N=40, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557
    |
    paclitaxel • Tasigna (nilotinib)
    over1year
    Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Institute (NCI) | Initiation date: Sep 2023 --> Dec 2023
    Trial initiation date
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557
    |
    paclitaxel • Tasigna (nilotinib)
    over1year
    Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557
    |
    paclitaxel • Tasigna (nilotinib)
    over1year
    Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Institute (NCI) | Initiation date: Jun 2023 --> Sep 2023
    Trial initiation date
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557
    |
    paclitaxel • Tasigna (nilotinib)
    over1year
    Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Dec 2022 --> Jun 2023
    Enrollment open • Trial initiation date
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557
    |
    paclitaxel • Tasigna (nilotinib)